Galectin Therapeutics Inc. Common Stock (GALT) Director Sells $66,330.00 in Stock

Galectin Therapeutics Inc. Common Stock (NASDAQ:GALT) Director Gilbert S. Omenn sold 11,000 shares of the stock in a transaction on Friday, September 7th. The stock was sold at an average price of $6.03, for a total value of $66,330.00. Following the completion of the sale, the director now owns 56,561 shares in the company, valued at approximately $341,062.83. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

NASDAQ GALT opened at $5.36 on Friday. Galectin Therapeutics Inc. Common Stock has a twelve month low of $1.28 and a twelve month high of $9.49. The stock has a market cap of $220.53 million, a price-to-earnings ratio of -10.94 and a beta of 2.66.

Galectin Therapeutics Inc. Common Stock (NASDAQ:GALT) last released its quarterly earnings results on Tuesday, August 14th. The company reported ($0.11) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.10) by ($0.01). equities research analysts forecast that Galectin Therapeutics Inc. Common Stock will post -0.44 EPS for the current fiscal year.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Argent Trust Co purchased a new stake in Galectin Therapeutics Inc. Common Stock during the second quarter valued at about $133,000. Laurel Wealth Advisors Inc. purchased a new stake in Galectin Therapeutics Inc. Common Stock during the first quarter valued at about $101,000. A.R.T. Advisors LLC raised its position in Galectin Therapeutics Inc. Common Stock by 60.2% during the first quarter. A.R.T. Advisors LLC now owns 57,775 shares of the company’s stock valued at $273,000 after purchasing an additional 21,704 shares in the last quarter. LPL Financial LLC purchased a new stake in Galectin Therapeutics Inc. Common Stock during the first quarter valued at about $112,000. Finally, First Allied Advisory Services Inc. purchased a new stake in Galectin Therapeutics Inc. Common Stock during the second quarter valued at about $223,000. Institutional investors and hedge funds own 13.60% of the company’s stock.

A number of brokerages recently issued reports on GALT. BidaskClub upgraded Galectin Therapeutics Inc. Common Stock from a “buy” rating to a “strong-buy” rating in a research report on Friday, June 15th. ValuEngine upgraded Galectin Therapeutics Inc. Common Stock from a “buy” rating to a “strong-buy” rating in a research report on Wednesday, August 29th. Finally, HC Wainwright reiterated a “buy” rating and issued a $12.00 price objective on shares of Galectin Therapeutics Inc. Common Stock in a research report on Thursday, August 16th. One analyst has rated the stock with a hold rating, four have assigned a buy rating and one has assigned a strong buy rating to the company. Galectin Therapeutics Inc. Common Stock currently has a consensus rating of “Buy” and an average price target of $6.94.

Galectin Therapeutics Inc. Common Stock Company Profile

Galectin Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic disease, skin disease, and cancer. The company's lead product candidate includes galectin-3 inhibitor (GR-MD-02), a galactoarabino-rhamnogalacturonan polysaccharide polymer for the treatment of liver fibrosis and liver cirrhosis in non-alcoholic steatohepatitis patients, as well as for the treatment of cancer.

Recommended Story: Stock Symbols Definition, Examples, Lookup

Insider Buying and Selling by Quarter for Galectin Therapeutics Inc. Common Stock (NASDAQ:GALT)

Receive News & Ratings for Galectin Therapeutics Inc. Common Stock Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galectin Therapeutics Inc. Common Stock and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit